Table 1: Summary of the impact of binding affinity changes in the CD8-Hla Class I interaction, the potential immunotherapy agonist and antagonist drug actions and their impact on immunological function.
Interaction | Binding Affinity (KD) | CD8-HLA Class I Drug Action | Immunological Outcome |
CD8-HLA Class I Wild Type | 145 µM | Nil | Normal T Cell Activity |
CD8-HLA Class I (Q115E) | 85 µM | Weak Agonist | Enhanced Activity Cognate Specificity Enhanced T Cell Specific Killing |
CD8-HLA-A2/Kb | 10 µM | Strong Agonist | Loss of Cognate HLA/Peptide Specificity Targets Killed by all T Cells |
CD8 -HLA Class I (D227K/T228A) | > 10,000 µM | Antagonist | Loss of T Cell Activity |